DUBLIN, September 19, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/fg8h7p/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Endometriosis is a common female health condition where the endometrial tissue, which is usually found inside the lining of the uterus, appear and grows outside the uterine cavity. Endometriosis mostly occurs in the fallopian tubes, ovaries, outer surface of the uterus, pelvic cavity, vagina, cervix, and bladder. Endometriosis has rarely been reported in more distant parts of the body such as the lungs, brain, and skin. The most common symptoms associated with endometriosis are pelvic pain, dysmenorrhea, excessive bleeding, and lower abdominal pain.
Some of the uncommon symptoms of endometriosis are rectal bleeding and hematuria. The detection of endometriosis in women is difficult because of the common symptoms associated with it. Endometriosis can be diagnosed by laparoscopy, ultrasound, pelvic exam, and biopsy of the inner lining of the uterus. In a biopsy, the tissues from the inner lining of the uterus of the patient are taken and tested using the biomarkers for the presence of endometriosis. Endometriosis is an incurable disease and relapses after the primary treatment. Currently, the treatment options for endometriosis include the usage of hormone therapy and analgesics to control the disease.
The analysts forecast the Global Endometriosis market will grow at a CAGR of 2.86 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market.
The report, the Global Endometriosis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Endometriosis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market.
According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market.
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Advertisement
Research and Markets (http://www.researchandmarkets.com/research/fg8h7p/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Endometriosis is a common female health condition where the endometrial tissue, which is usually found inside the lining of the uterus, appear and grows outside the uterine cavity. Endometriosis mostly occurs in the fallopian tubes, ovaries, outer surface of the uterus, pelvic cavity, vagina, cervix, and bladder. Endometriosis has rarely been reported in more distant parts of the body such as the lungs, brain, and skin. The most common symptoms associated with endometriosis are pelvic pain, dysmenorrhea, excessive bleeding, and lower abdominal pain.
Some of the uncommon symptoms of endometriosis are rectal bleeding and hematuria. The detection of endometriosis in women is difficult because of the common symptoms associated with it. Endometriosis can be diagnosed by laparoscopy, ultrasound, pelvic exam, and biopsy of the inner lining of the uterus. In a biopsy, the tissues from the inner lining of the uterus of the patient are taken and tested using the biomarkers for the presence of endometriosis. Endometriosis is an incurable disease and relapses after the primary treatment. Currently, the treatment options for endometriosis include the usage of hormone therapy and analgesics to control the disease.
The analysts forecast the Global Endometriosis market will grow at a CAGR of 2.86 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market.
The report, the Global Endometriosis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Endometriosis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market.
According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Rate of Incidence and Prevalence
08. Market Segmentation by Type of Therapy
09. Market Segmentation by Route of Administration and Type of Dosage Form
10. Pipeline Portfolio
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
21. Other Reports in this Series
Companies Mentioned:
- Abbvie
- AstraZeneca
- Bayer
- Pfizer.
- Astellas
- Abbvie
- Repros
- Sanofi
- Takeda
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
